We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sandoz to Supreme Court: Circuit Erred in Ruling 180-Day Notification Required After Biosimilar Approval
Sandoz to Supreme Court: Circuit Erred in Ruling 180-Day Notification Required After Biosimilar Approval
Sandoz is arguing the Federal Circuit misinterpreted federal law when ruling that biosimilar makers must wait six months after an FDA approval to launch a product.